| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c52ab6bada7c50e8935c982245faadb7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-34 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate |
2020-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25927da6243df9703461f0496f7f4bf4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdb82e616efe06d7d2add7a61eae2eac |
| publicationDate |
2022-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022204509-A1 |
| titleOfInvention |
Pyrimido five-membered heterocyclic compound and use thereof as mutant idh2 inhibitor |
| abstract |
The present invention relates to a pyrimido five-membered heterocyclic compound and use thereof as a mutant IDH2 inhibitor. Specifically, disclosed in the present invention are a pyrimido five-membered heterocyclic compound capable of serving as a mutant IDH2 inhibitor, or a stereoisomer or a tautomer, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The present invention also relates to a pharmaceutical composition comprising the compound, and use thereof in the preparation of a medicament for preventing and/or treating a disease mediated by mutant IDH2. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107556366-A |
| priorityDate |
2019-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |